Literature DB >> 27657903

Layered sellar reconstruction with avascular free grafts: Acceptable alternative to the nasoseptal flap for repair of low-volume intraoperative cerebrospinal fluid leak.

Christopher R Roxbury1, Tiffany Saavedra, Murugappan Ramanathan, Michael Lim, Masaru Ishii, Gary L Gallia, Douglas D Reh.   

Abstract

BACKGROUND: Although the nasoseptal flap has become the method of choice for reconstruction of intraoperative cerebrospinal fluid (CSF) leak in endoscopic minimally invasive surgery of the skull base, layered avascular graft techniques, including allografts and middle turbinate mucosal autografts, may provide comparable reconstructive success with decreased nasal morbidity.
OBJECTIVE: To describe a method of reconstruction of intraoperative CSF leak in endoscopic surgery of the sella turcica and analyze its postoperative success rate and associated comorbidities.
METHODS: A retrospective review of expanded endonasal sellar tumor resections from 2008-2014 was performed, and cases of layered intraoperative skull base reconstruction with avascular free grafts were identified. Demographic factors and comorbidities that predisposed to reconstruction failure (obstructive sleep apnea, obesity) were determined. Reconstruction-related nasal complications were also identified. Postoperative CSF leak rate was determined, and statistical analysis was performed to identify predictive factors for reconstructive failure.
RESULTS: Seventy-three cases were identified. Layered closure with avascular free grafts was performed. There were five cases of postoperative CSF leak (6.85%). The mean follow-up was 19 months (range, 1-76 months). Intraoperative high-flow CSF leak was a significant predictor of reconstruction failure on univariate (odds ratio 22 [95% confidence interval, 2.26-214]; p = 0.008) and multivariate analysis (odds ratio 33.6 [95% confidence interval, 2.30-492]; p = 0.010). There were no significant differences in postoperative leak rates among bony overlay graft types. There were five patients (7.9%) who experienced persistent crusting after surgery. There were no significant differences in crusting rates between allografts and mucosal grafts. There were no postoperative mucoceles.
CONCLUSION: In cases of low-volume intraoperative CSF leak, layered skull base repair with avascular free grafts was an acceptable alternative to the nasoseptal flap, which may reduce prolonged sinonasal healing and donor-site morbidities.

Entities:  

Mesh:

Year:  2016        PMID: 27657903     DOI: 10.2500/ajra.2016.30.4356

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  5 in total

1.  Reality bites: The establishment of accountable care organizations in otolaryngology.

Authors:  Troy D Woodard
Journal:  Am J Rhinol Allergy       Date:  2016-09       Impact factor: 2.467

2.  Heterogeneity in Outcome Reporting in Endoscopic Endonasal Skull Base Reconstruction: A Systematic Review.

Authors:  Christina Dorismond; Griffin D Santarelli; Brian D Thorp; Adam J Kimple; Charles S Ebert; Adam M Zanation
Journal:  J Neurol Surg B Skull Base       Date:  2020-08-07

3.  An Algorithm for Sellar Reconstruction Following the Endoscopic Endonasal Approach: A Review of 300 Consecutive Cases.

Authors:  Edward C Kuan; Frederick Yoo; Pratik B Patel; Brooke M Su; Marvin Bergsneider; Marilene B Wang
Journal:  J Neurol Surg B Skull Base       Date:  2017-08-28

4.  Endoscopic Reconstruction of Skull Base Defects Using Tutoplast.

Authors:  Ghassan Alokby; Kholoud Mohammed AlAmari; Jamal Mohammed S Abdullah; Mohammed Tayed Hazazi; Fawaz Makki
Journal:  Allergy Rhinol (Providence)       Date:  2021-04-09

5.  Skull base repair following endonasal pituitary and skull base tumour resection: a systematic review.

Authors:  Danyal Z Khan; Ahmad M S Ali; Chan Hee Koh; Neil L Dorward; Joan Grieve; Hugo Layard Horsfall; William Muirhead; Thomas Santarius; Wouter R Van Furth; Amir H Zamanipoor Najafabadi; Hani J Marcus
Journal:  Pituitary       Date:  2021-05-10       Impact factor: 4.107

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.